http://orcid.org/0000-0002-8322-475X
Figures & data
Figure 1. ‘Easy’ and ‘difficult’ patients. The ‘easy’ patients present some characteristics (e.g., no brain metastasis, low tumor burden, normal LDH) that result in active immune surveillance against cancer cells. Such immune surveillance may be pre-existing and responsible for reaching complete response. On the other hand, immune surveillance is impaired in difficult patients, who commonly present brain metastasis, high tumor burden, and high LDH.
Figure 2. Effects of BRAF-MEK inhibition on melanoma cells and tumor microenvironment. Therapy with BRAF and MEK inhibitors induces profound changes in antigen display, and expression of MHC, IFNAR, and CD73 on tumor cells. These changes are also evident on tumor microenvironment: namely they result in reduction of adenosine, diminished Treg and MDSC presence, and increased activity of CD4-CD8+ lymphocytes.
